"Nitriles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Organic compounds containing the -CN radical. The concept is distinguished from CYANIDES, which denotes inorganic salts of HYDROGEN CYANIDE.
| Descriptor ID |
D009570
|
| MeSH Number(s) |
D02.626
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Nitriles".
Below are MeSH descriptors whose meaning is more specific than "Nitriles".
This graph shows the total number of publications written about "Nitriles" by people in this website by year, and whether "Nitriles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 2 | 3 |
| 2015 | 2 | 0 | 2 |
| 2016 | 2 | 3 | 5 |
| 2017 | 13 | 41 | 54 |
| 2018 | 21 | 25 | 46 |
| 2019 | 9 | 12 | 21 |
| 2020 | 2 | 17 | 19 |
| 2021 | 1 | 14 | 15 |
To return to the timeline, click here.
Below are the most recent publications written about "Nitriles" by people in Profiles.
-
Supervised Molecular Dynamics (SuMD) Insights into the mechanism of action of SARS-CoV-2 main protease inhibitor PF-07321332. J Enzyme Inhib Med Chem. 2021 Dec; 36(1):1646-1650.
-
Challenges of short substrate analogues as SARS-CoV-2 main protease inhibitors. Bioorg Med Chem Lett. 2021 10 15; 50:128333.
-
The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS). Leukemia. 2021 10; 35(10):2917-2923.
-
Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib. Am J Hematol. 2021 11 01; 96(11):E408-E410.
-
Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials. Int Immunopharmacol. 2021 Oct; 99:108027.
-
Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp14 RNA cap methyltransferase. Biochem J. 2021 07 16; 478(13):2481-2497.
-
The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells. Nat Commun. 2021 07 01; 12(1):4068.
-
Structure-guided design of a perampanel-derived pharmacophore targeting the SARS-CoV-2 main protease. Structure. 2021 08 05; 29(8):823-833.e5.
-
Ruxolitinib for Severe COVID-19-Related Hyperinflammation in Nonresponders to Steroids. Acta Haematol. 2021; 144(6):620-626.
-
SARS-CoV-2 infection in a pediatrics STAT1 GOF patient under Ruxolitinib therapy-a matter of balance? J Clin Immunol. 2021 10; 41(7):1502-1506.